Fundraising Fox
Celea Therapeutics
3 known investors
Find your way into Celea Therapeutics
Sign up to see every warm intro you have to Celea Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Celea Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Celea develops deupirfenidone, a pulmonary therapeutic targeting idiopathic pulmonary fibrosis in partnership with physicians and patient advocacy organizations.
Investors · 3
How we know: PureTech Health's portfolio page · funding news · allsci.com · Not right? Tell us
How we know: RA Capital's portfolio page · funding news · allsci.com · Not right? Tell us
How we know: funding news · allsci.com · Not right? Tell us
Funding
SEC filings, press & company announcements$180M disclosed across 1 of 2 rounds · 2026
- $180MraisedJul 2026 · 3 sources
Leaps by Bayer, PureTech Health, RA Capital Management
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Celea Therapeutics do?
- Celea develops deupirfenidone, a pulmonary therapeutic targeting idiopathic pulmonary fibrosis in partnership with physicians and patient advocacy organizations.
- Who are Celea Therapeutics's investors?
- Celea Therapeutics's investors include PureTech Health, RA Capital, Leaps by Bayer.
- How much funding has Celea Therapeutics raised?
- Celea Therapeutics has disclosed $180M raised across 1 of its 2 known rounds.